tiprankstipranks
Samil Pharmaceutical Co., Ltd. (KR:000520)
:000520
South Korea Market

Samil Pharmaceutical Co., Ltd. (000520) Stock Statistics & Valuation Metrics

Followers

Total Valuation

Samil Pharmaceutical Co., Ltd. has a market cap or net worth of ₩137.49B. The enterprise value is ₩310.98K.
Market Cap₩137.49B
Enterprise Value₩310.98K

Share Statistics

Samil Pharmaceutical Co., Ltd. has 21,691,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,691,810
Owned by Insiders
Owned by Institutions

Financial Efficiency

Samil Pharmaceutical Co., Ltd.’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -6.80%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-6.80%
Return on Capital Employed (ROCE)-0.13
Revenue Per Employee359.60M
Profits Per Employee-59.25M
Employee Count585
Asset Turnover0.57
Inventory Turnover4.10

Valuation Ratios

The current PE Ratio of Samil Pharmaceutical Co., Ltd. is ―. Samil Pharmaceutical Co., Ltd.’s PEG ratio is -0.01.
PE Ratio
PS Ratio0.98
PB Ratio1.54
Price to Fair Value1.54
Price to FCF-15.23
Price to Operating Cash Flow-5.07K
PEG Ratio-0.01

Income Statement

In the last 12 months, Samil Pharmaceutical Co., Ltd. had revenue of 210.37B and earned -34.59B in profits. Earnings per share was -1.63K.
Revenue210.37B
Gross Profit67.44B
Operating Income-23.94B
Pretax Income-37.16B
Net Income-34.59B
EBITDA-10.72B
Earnings Per Share (EPS)-1.63K

Cash Flow

In the last 12 months, operating cash flow was -26.12M and capital expenditures -7.41B, giving a free cash flow of -7.43B billion.
Operating Cash Flow-26.12M
Free Cash Flow-7.43B
Free Cash Flow per Share-342.63

Dividends & Yields

Samil Pharmaceutical Co., Ltd. pays an annual dividend of ₩72.727, resulting in a dividend yield of ―
Dividend Per Share₩72.727
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.06
52-Week Price Change-36.34%
50-Day Moving Average
200-Day Moving Average
Relative Strength Index (RSI)
Average Volume (3m)91.98K

Important Dates

Samil Pharmaceutical Co., Ltd. upcoming earnings date is Nov 18, 2026, TBA (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date

Financial Position

Samil Pharmaceutical Co., Ltd. as a current ratio of 0.44, with Debt / Equity ratio of 140.22%
Current Ratio0.44
Quick Ratio0.25
Debt to Market Cap0.79
Net Debt to EBITDA-14.70
Interest Coverage Ratio-2.73

Taxes

In the past 12 months, Samil Pharmaceutical Co., Ltd. has paid -2.49B in taxes.
Income Tax-2.49B
Effective Tax Rate0.07

Enterprise Valuation

Samil Pharmaceutical Co., Ltd. EV to EBITDA ratio is -33.90, with an EV/FCF ratio of -26.89.
EV to Sales1.73
EV to EBITDA-33.90
EV to Free Cash Flow-26.89
EV to Operating Cash Flow-59.99

Balance Sheet

Samil Pharmaceutical Co., Ltd. has ₩6.11B in cash and marketable securities with ₩176.05B in debt, giving a net cash position of -₩169.93B billion.
Cash & Marketable Securities₩6.11B
Total Debt₩176.05B
Net Cash-₩169.93B
Net Cash Per Share-₩7.83K
Tangible Book Value Per Share₩6.01K

Margins

Gross margin is 32.13%, with operating margin of -11.38%, and net profit margin of -16.44%.
Gross Margin32.13%
Operating Margin-11.38%
Pretax Margin-17.66%
Net Profit Margin-16.44%
EBITDA Margin-5.10%
EBIT Margin-11.38%

Analyst Forecast

The average price target for Samil Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast-4.54%
EPS Growth Forecast-88.02%

Scores

Smart ScoreN/A
AI Score